GNPX

Quote

Short

News

Articles

Message Board

Genprex Inc. (NASDAQ : GNPX ) News

Genprex Inc. (NASDAQ: GNPX) News Releases

GNPX News Releases

May 26, 2026 08:00:00 am

PR Newswire

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

May 14, 2026 08:00:00 am

PR Newswire

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

April 30, 2026 08:00:00 am

PR Newswire

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

April 28, 2026 07:00:00 am

PR Newswire

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

April 22, 2026 07:00:00 am

PR Newswire

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

April 21, 2026 07:00:00 am

PR Newswire

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy

April 20, 2026 07:00:00 am

PR Newswire

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

March 18, 2026 07:00:00 am

PR Newswire

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

March 10, 2026 07:00:00 am

PR Newswire

Genprex to Participate at BIO Europe Spring 2026

February 23, 2026 08:00:00 am

PR Newswire

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account